Whitehawk Therapeutics Stock (NASDAQ: WHWK)

Whitehawk Therapeutics

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics Inc

Earnings

Press Releases

Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company

Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals

Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights

WHWK

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Agenus

Anixa Biosciences

Cibus

Climb Bio

Caribou Biosciences

CervoMed

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

MediciNova

OncoCyte

Pyxis Oncology

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Senti Biosciences

TScan Therapeutics

Instil Bio

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Exicure

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Comments

Whitehawk Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell